The multiyear effort will work to spread awareness about non-opioid options to manage acute and chronic pain, including by educating retired players, NFLA chapter presidents and staff, and youth sports organizations.

According to court documents the company, "knowingly filled prescriptions for controlled substances ... for patients exhibiting suspicious and drug-seeking behavior, including patients that repeatedly requested early refills, paid thousands of dollars in cash for their prescriptions, or requested that prescriptions be sent to suspicious or inappropriate locations, including hotels, casinos and elementary schools.”

The panel will discuss how – and why – the crisis is affecting certain populations. It is presented by the Partnership for a Drug-Free New Jersey and the Office of the New Jersey Coordinator of Addiction Responses and Enforcement Strategies.

The city enlisted software provider Quickbase for a dispatch system that, in short, gets a life-saving prescription to those who need it, and quickly.

The grant is part of the latest round of funding from the Foundation for Opioid Response Efforts, which announced a total of $10.9 million over three years to support prevention programs across nine organizations nationwide.

The funds will go toward state and local programs focused on treatment, prevention and other strategies to combat the epidemic.

The organization was awarded a one-year $525,000 New Jersey Department of Labor and Workforce Development grant to launch the initiative for adults impacted by the opioid epidemic in northern New Jersey.

The agreement, which admits no wrongdoing, is the latest for the Parsippany-based drugmaker.

Bloomberg Philanthropies picked just three cities from the U.S. as winners for the worldwide competition.

It's the second New Jersey-based pharmaceutical company to make such an announcement in the last week.

With funding from the Division of Mental Health and Addiction Services, experts will help providers address trauma, compassion fatigue and burnout through the company's OPTICS program.

The New Brunswick-based drug maker will also end the manufacturing of the drugs and their distribution across the nation.